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Abstract
Objective—Autosomal recessive hypercholesterolemia (ARH) is a rare inherited disorder
characterized by extremely high total and low-density lipoprotein cholesterol levels that has been
previously linked to mutations in LDLRAP1. We identified a family with ARH not explained by
mutations in LDLRAP1 or other genes known to cause monogenic hypercholesterolemia. The aim
of this study was to identify the molecular etiology of ARH in this family.
Approach and Results—We used exome sequencing to assess all protein coding regions of the
genome in three family members and identified a homozygous exon 8 splice junction mutation (c.
894G>A, also known as E8SJM) in LIPA that segregated with the diagnosis of
hypercholesterolemia. Since homozygosity for mutations in LIPA is known to cause cholesterol
ester storage disease (CESD), we performed directed follow-up phenotyping by non-invasively
measuring hepatic cholesterol content. We observed abnormal hepatic accumulation of cholesterol
in the homozygote individuals, supporting the diagnosis of CESD. Given previous suggestions of
cardiovascular disease risk in heterozygous LIPA mutation carriers, we genotyped E8SJM in
>27,000 individuals and found no association with plasma lipid levels or risk of myocardial
infarction, confirming a true recessive mode of inheritance.
Conclusions—By integrating observations from Mendelian and population genetics along with
directed clinical phenotyping, we diagnosed clinically unapparent CESD in the affected
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individuals from this kindred and addressed an outstanding question regarding risk of
cardiovascular disease in LIPA E8SJM heterozygous carriers.
Keywords
hypercholesterolemia; genetics; myocardial infarction
Introduction
Monogenic hypercholesterolemia is a disorder of lipid metabolism in which extremely
elevated levels of total and low-density lipoprotein cholesterol (LDL-C) are caused by a
single gene mutation. Mutations in LDLR1, APOB2, and PCSK93 cause autosomal dominant
hypercholesterolemia, a disease affecting at least 1 in 500 individuals. Autosomal recessive
hypercholesterolemia (ARH) occurs much less frequently – estimated to occur in
1:1,000,000 live births – and has been linked to mutations in LDLRAP14. In some families
with apparent monogenic hypercholesterolemia, an underlying molecular defect cannot be
identified in any of these known genes.
We identified a family with apparent Mendelian inheritance of high LDL-C levels that was
not caused by mutations in any of the above genes known to affect LDL-C. The small size
of the family pedigree precluded use of traditional linkage mapping. Next-generation
sequencing (NGS), a rapid and low-cost method to perform large-scale DNA sequencing5,
has emerged as an important tool for uncovering the cause of inherited diseases6. In this
study, we used exome sequencing, a technique in which NGS is used to assess all protein-
coding regions of the genome, in three individuals from this family to search for a rare
genetic variant that co-segregated with high LDL-C levels.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
Subject recruitment
The proband (Figure 1; individual II-2) presented to the Lipid Clinic at the Academic
Medical Center, University of Amsterdam, the Netherlands at the age of 23. Her LDL-C
level exceeded the 99th percentile when adjusted for age and gender. She had two siblings
(one of which was a monozygotic twin), both of whom shared LDL-C levels exceeding the
99th percentile. Her father and mother, a non-consanguineous union, had LDL-C levels at
the 25th and 78th percentile, respectively, when adjusted for age and gender (Figure 1). The
proband and both siblings lacked hepatosplenomegaly on abdominal examination. Based on
the pedigree, an autosomal recessive mode of inheritance appeared to be the most likely
explanation for the family’s phenotype.
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To identify the molecular basis of hypercholesterolemia in this family, exome sequencing
was performed in the proband, the proband’s father, and the proband’s brother (Figure 1;
individuals II-2, I-1, and II-1, respectively). A total of 32,950,014 bases across the exome
were targeted and each sample was sequenced with an average of 126-fold coverage across
the target. Across the exome, 82% of targeted bases were covered with >30-fold coverage.
This yielded a mean of 36,986 single nucleotide variants per individual. The average ratio of
heterozygous to homozygous alleles (1.6) and ratio of transitions to transversions (2.7) per
individual were expected and similar to contemporary large-scale population sequencing
projects7.
Exome Sequencing Analysis
To exclude genetic variation unlikely to be responsible for this family’s
hypercholesterolemia, we relied on three main assumptions: (1) the causal variant(s) alters
the gene’s corresponding protein product; (2) the causal variant(s) is inherited in an
autosomal recessive fashion; and (3) the causal variant(s) exhibits complete penetrance. For
the first assumption, we only included single nucleotide substitutions and short insertions or
deletions that were predicted to alter the protein sequence.
We next included either 1) compound heterozygous changes (a heterozygous variant in both
affected siblings and the father located in a gene that also contained a separate heterozygous
variant in both affected siblings not found in the father) or 2) variants that were homozygous
in both affected siblings and heterozygous in the unaffected father. Finally, we excluded
variants from further consideration if they were present in the general population at a
frequency of greater than 1%, or if they were present in either heterozygous or homozygous
form in the exome sequences of 235 individuals with very low LDL-C levels.
After applying this analysis, the number of variants shared among the three family members
was reduced from 54,301 to two candidate single nucleotide substitutions. One was a
synonymous variant predicted to alter the splice donor site of the eighth exon in the gene
lipase A, lysosomal acid, cholesterol esterase (LIPA) (c.894G>A, in the last nucleotide of
exon 8) and the other was a missense change predicted to result in the substitution of
Alanine for Proline at residue 384 in the gene ATP/GTP binding protein-like 2 (AGBL2).
Since previous reports showed a link between the c.894G>A mutation – also known as the
Exon 8 Splice Junction Mutation (E8SJM) – in LIPA and cholesterol ester storage disease
(CESD)8, a disorder with mixed hyperlipidemia as part of the phenotypic presentation, we
focused on a potential diagnosis of CESD as the most likely cause for this family’s apparent
autosomal recessive hypercholesterolemia.
Functional assessment of E8SJM
Sanger sequencing was performed and confirmed the presence of the E8SJM allele in the
homozygous state in affected individuals and in the heterozygous state in both unaffected
parents. Haplotype analysis revealed that both maternal and paternal E8SJM alleles were on
the same haplotype as previously reported for this mutation (“Haplotype 1” from Fasano et
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al.9). This does not appear to be a result of consanguinity as the proband was found to share
53% and 49% of her exome identical-by-descent with her brother and father, respectively,
eliminating cryptic consanguinity. The skipping of exon 8 was confirmed in all individuals
carrying the mutated allele (Figure 2).
Although the affected individuals did not present with clinically apparent hepatic disease,
given the previous reports linking mutations in LIPA with CESD, we reassessed the affected
individuals for the level of hepatic cholesterol ester using magnetic resonance spectroscopy
(MRS), a technique shown to correlate well with histologic lipid distribution10. In
individuals II-1, II-2 and II-3, MRS demonstrated a distinct cholesterol peak separate from
the larger and expected triglyceride peak at 1.25 ppm. The ratios between triglyceride at
1.25 ppm and cholesterol at 0.9 ppm were 0.57, 0.34 and 0.40 for individuals II-1, II-2 and
II-3 respectively, indicating the presence of an excess of hepatic cholesterol deposition
(Figure 3). The elevated cholesterol peak at 0.9 ppm was not identified in individual I-1.
Individuals II-1, II-2, and II-3 had normal hepatic size as measured on the magnetic
resonance imaging portion of the study.
Population impact of E8SJM
Given previous reports suggesting that serum lipids levels are increased in heterozygous
E8SJM carriers11, we genotyped the E8SJM variant in 13,194 individuals of European
ancestry. Triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and LDL-C
levels were available in 13,194, 13,144, and 12,805 individuals, respectively. In these
individuals, the E8SJM was present with an allele frequency of 0.16% and no association
was observed with any of these three lipid fractions (Table 1).
Furthermore, to also assess the impact of partial loss of LIPA function on risk for myocardial
infarction (MI) or coronary artery disease (CAD) in the population, we genotyped the
E8SJM variant in 27,472 individuals of European ancestry (12,747 cases with MI/CAD,
14,725 controls free of MI and CAD). In these individuals, the E8SJM was present with an
allele frequency of 0.11% and there was no association of E8SJM with risk for MI or CAD
(odds ratio for MI or CAD in carriers = 0.85; p-value = 0.6).
Discussion
Traditional Mendelian genetic analyses have relied on positional cloning and sequencing the
genetic regions under linked peaks to identify causal defects responsible for monogenic
disorders. These techniques are unfortunately of limited utility in small families such as the
one presented in the current study. NGS, however, now allows for the potential
identification of candidate genes underlying Mendelian disorders in families regardless of
the pedigree size. In this study, we performed NGS across the exome in three individuals
from a family with suspected ARH and identified homozygous E8SJM alleles in LIPA that
co-segregated with the clinical diagnosis of hypercholesterolemia.
Lysosomal acid lipase (LAL), encoded by the gene LIPA, is responsible for hydrolyzing
cholesterol esters and triglycerides that are delivered to lysosomes. Mutations in LIPA that
completely inactivate LAL have previously been identified as the molecular cause of
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Wolman disease, a rapidly lethal disease of infancy, characterized by hepatosplenomegaly,
abdominal distension, adrenal calcification, and steatorrhea with extensive storage of
cholesterol esters and triglycerides in the liver, spleen, and other organs in the first weeks of
life12, 13.
A related disorder, cholesterol ester storage disease (CESD), is associated with a less severe
phenotype14, 15. Characterized by massive hepatic accumulation of cholesterol esters,
hepatomegaly, steatosis, and mixed hyperlipidemia, CESD is caused by mutations in LIPA
that result in near complete loss of LAL activity with enough residual enzymatic activity to
hydrolyze triglycerides but not cholesterol esters.
The identification of homozygous E8SJM alleles in LIPA was surprising in this family, as it
has been previously identified as a cause of CESD16. E8SJM has been shown to cause sub-
total loss of gene function resulting in only 2–4% normally spliced LIPA mRNA transcripts
and LAL activity16. Homozygosity for E8SJM has previously been reported in individuals
with hepatic disease and mixed hyperlipidemia, characterized by elevated levels of LDL-C
and TG with decreased HDL-C levels (Table 2).
The homozygous individuals in the current study presented with a very different phenotype
and would not have been clinically diagnosed with CESD. Their lipid profile is
characterized by extremely elevated LDL-C with normal to high HDL-C and normal TG
levels while previously described E8SJM homozygotes have been noted to have increased
LDL-C with low HDL-C and elevated TG levels (Table 2). In addition, the hepatic
phenotype in the homozygous individuals from the current study appears to consist of only a
subtle elevation in ALT (Table 2) without the typical hepatosplenomegaly (hepatomegaly
and splenomegaly are present in >99% and 74% of patients with CESD, respectively17).
Given the previous associations between LIPA E8SJM and CESD (for homozygous carriers)
and polygenic hypercholesterolemia and potentially increased risk of MI/CAD (for
heterozygote carriers)11, we performed directed phenotypic and genetic follow-up analyses
to address two questions: 1) Do the homozygous carriers within this pedigree have hepatic
hallmarks of CESD?; and 2) Are the heterozygote parents at increased risk for MI/CAD?
Using non-invasive hepatic MRS, we demonstrated the presence of abnormal quantities of
hepatic cholesterol in the homozygous E8SJM carriers of this family. This finding is entirely
consistent with previously reported hepatic MRS findings in patients with LAL deficiency
(previously reported MRS ratios 0.24–0.5)18 and confirms the diagnosis of CESD in the
three offspring. A liver biopsy was not thought to be clinically indicated given the absence
of increased transaminase levels combined with previous reports surrounding the causal role
of LIPA E8SJM in CESD and the confirmatory MRS findings. While a seemingly subtle
distinction, this diagnosis is clinically important as the offspring should be followed for the
progression of hepatic disease and may be potential candidates in the future for enzyme
replacement therapy that is currently in development19. In addition, this finding illustrates
that CESD may have a more variable phenotypic presentation than previously appreciated.
To assess the potential of increased cardiovascular disease risk in the heterozygous parents,
we genotyped LIPA E8SJM in the population. The population frequency of LIPA E8SJM
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has previously been estimated to be between 0.21% and 0.25% in individuals of European
descent20,21, and has been associated with a polygenic hypercholesterolemia phenotype11,
prompting the hypothesis that it may be associated with increased risk of MI/CAD. We now
firmly establish that this variant is rarer than previously estimated (allele frequency =
0.11%). We consider our estimate of the carrier frequency for European individuals to be
more accurate than previous reports given the larger numbers of individuals assessed
(27,472 in the current study compared with 4,112 in a previous report21).
In this large genetic study, we observed no association of heterozygosity with plasma lipid
levels or risk for MI/CAD. Although we cannot definitively exclude a weak association with
MI/CAD or serum lipid levels, we had 93% power to detect a 2-fold increased risk of
MI/CAD at an alpha of 0.05 and 94% power to detect a variant explaining 0.1% of the
phenotypic variance in LDL-C at an alpha of 0.05. These findings suggest that the E8SJM
acts in a truly recessive fashion and that heterozygous loss of function does not result in a
distinct lipid or MI phenotype.
It is uncertain why the presentation of CESD in this family differed from those described in
previous reports. The E8SJM in this family occurs on the same haplotype as previously
reported for this mutation, supporting a common founder ancestor for this mutation and
suggesting that the milder-than-expected phenotype is not explained by a simple difference
of local genetic background in LIPA. In addition to the E8SJM in LIPA, we identified rare
homozygous alleles in AGBL2 carried by all three affected offspring. At this time it is
unclear what, if any, phenotypic effect this confers. There may be a genetic factor (in
AGBL2 or elsewhere) conferring a protective hepatic effect; however, given the lack of
family members with hepatic disease as a comparator, we are underpowered to discover
such a variant.
In summary, we report homozygosity for E8SJM in LIPA as a cause of clinically unapparent
CESD presenting as autosomal recessive hypercholesterolemia. The discovery of E8SJM in
LIPA in this family highlights both the blessing and the curse of using NGS in genetic
discovery studies; along with the potential unbiased discovery of the causal variant comes
tens of thousands of additional variants unrelated to the phenotype of interest and the
possibility of unexpected findings. We suggest integrating Mendelian and population
genetics with directed clinical testing as a powerful way to discern signal from noise in the
next generation of genetic discovery studies.
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Autosomal recessive hypercholesterolemia is a rare inherited disorder previously linked
to mutations in LDLRAP1. In this report, we use exome sequencing and clinical
phenotyping to diagnose cholesterol ester storage disease (CESD) in a small family with
apparent autosomal recessive hypercholesterolemia. CESD is caused by mutations in
LIPA and typically presents with hepatic disease and mixed hyperlipidemia. This study
reveals a broader phenotypic presentation for loss of function mutations in LIPA than
previously appreciated and suggests that LIPA mutations may be considered in the
clinical evaluation of autosomal recessive hypercholesterolemia.
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Pedigree of the family demonstrating autosomal recessive hypercholesterolemia. Laboratory values are shown below each
individual (TC = total cholesterol; LDL = low density lipoprotein cholesterol; HDL = high density lipoprotein cholesterol; TG =
triglycerides; ALT = alanine aminotransferase). Individuals II-2 and II-3 are identical twins.
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RT-PCR of LIPA demonstrating skipping of exon 8 as a result of E8SJM. The upper and lower bands correspond to the expected
products either containing (301 bp) or lacking (229 bp) exon 8, respectively. Control cDNA from individuals not carrying
E8SJM demonstrates the expected product containing exon 8. Heterozygous carriers of E8SJM (Individuals I-1 and I-2)
demonstrate the presence of one wild-type transcript and one transcript lacking exon 8, whereas homozygous E8SJM carriers
(Individuals II-2 and II-3) demonstrate complete skipping of exon 8. M = molecular weight marker.
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Water suppressed MRS spectra demonstrating hepatic cholesterol deposition in homozygous carriers of LIPA E8SJM. R = ratio
between peaks at 1.25 ppm and 0.9 ppm. Panel a: Individual I-1, the unaffected father of the proband, demonstrates a normal
ratio. Panel b-d: Individuals II-2, II-3, and II-1, respectively demonstrate elevated ratios.
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